David V. Goeddel, PhD
Partner Emeritus at The Column Group
About
David V. Goeddel led creation of the first marketed recombinant therapeutics (including insulin and growth hormone), and built Tularik to IPO and sale to Amgen, with a rare scientist-CEO perspective.
Invests in
BiotechHealthtech
Colleagues at The Column Group
Aadit Shah
Principal at The Column Group
Arnav Mehta, MD, PhD
Venture Partner at The Column Group
Carla Daniel
Partner at The Column Group
Craig Parker
Venture Partner at The Column Group
David Goeddel
Managing Partner at The Column Group
Helen Kim
Partner at The Column Group
Hui Tian
Partner at The Column Group
Hui Tian, PhD
Partner at The Column Group